Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry

Gil Hevroni, Katie Thoren, Dan C. Qu, Elizabeth Lyubchenko, Elena Bosack, James E. Hoffman, Ola Landgren, Benjamin Diamond, Dickran Kazandjian, David G. Coffey

Blood (2024) 144 (Supplement 1): 6847.

https://doi.org/10.1182/blood-2024-205107

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2024) 144 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2024-193966

Published: 2024

Journal Articles

Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Palak Bajaj, Ola Landgren, Damian J. Green, David G. Coffey

Blood (2024) 144 (Supplement 1): 252.

https://doi.org/10.1182/blood-2024-204426

Published: 2024

Journal Articles

Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab

Andrew Kowalski, Jill Lykon, Benjamin Diamond, David G. Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman, Dickran Kazandjian, Ola Landgren

Blood (2024) 144 (Supplement 1): 932.

https://doi.org/10.1182/blood-2024-203426

Published: 2024

Journal Articles

Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma

Andrew Kowalski, David G. Coffey, Benjamin Diamond, James E. Hoffman, Marcella Kaddoura, Jill Lykon, Francesco Maura, Yahirini Rodriguez-Martinez, Suzan Rosen, Faika Shah, Dennis Verducci, Ola Landgren, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2024-203763

Published: 2024

Journal Articles

Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Blood (2024) 144 (Supplement 1): 4832.

https://doi.org/10.1182/blood-2024-205942

Published: 2024

Journal Articles

Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias

Yong Zhang, David G. Coffey, Elizabeth Hill, Frank Cross, Jr., Reena Philip, Marc R. Theoret, Ola Landgren, Andrea C Baines, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2024-202574

Published: 2024

Journal Articles

Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase inhibition and CAR T-cell therapy

David G Coffey, Pinar Ataca Atilla, Erden Atilla, Ola Landgren, Andrew J Cowan, Sylvain Simon, Margot Pont, Melissa L. Comstock, Geoffrey R Hill, Stanley R. Riddell, Damian J Green

Blood blood.2024025231.

https://doi.org/10.1182/blood.2024025231

Published: 2024

Includes: Supplemental data

Journal Articles

Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy

George Mo, Sang Yun Lee, David G. Coffey, Valentin Voillet, IIan Kirsch, Damian J. Green, Raphael Gottardo, David G. Maloney, Oliver W. Press, Brian G. Till

Blood (2022) 140 (Supplement 1): 7460–7461.

https://doi.org/10.1182/blood-2022-159664

Published: 2022

Journal Articles

Spinal Disease Predicts CNS Involvement in Patients with Plasma Cell Leukemia

Dominique DeGraaff, David G. Coffey

Blood (2021) 138 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2021-154537

Published: 2021

Journal Articles

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, Margot Pont, Blythe Duke Sather, Cameron J. Turtle, Brian G. Till, Edward Libby, David G. Coffey, Sherilyn A. Tuazon, Brent L. Wood, Ted A Gooley, Qian Vicky Wu, Mazyar Shadman, Jordan Gauthier, Aude G. Chapuis, Filippo Milano, David G. Maloney, Stanley R. Riddell, Damian J. Green

Blood (2021) 138 (Supplement 1): 551.

https://doi.org/10.1182/blood-2021-154170

Published: 2021

Journal Articles

The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations

Blood (2021) 138 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2021-148095

Published: 2021

Journal Articles

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2021-145927

Published: 2021

Journal Articles

Peripheral Blood Single-Cell Genotyping and Phenotyping in Multiple Myeloma Reveals Shared Mutations across Multiple Hematopoietic Cell Lineages

David G. Coffey, Aditi Agrawal, Maurizio Morri, Edus H. Warren, Robert Durruthy-Durruthy, Marc Arribas-Layton, Yue Wang, Norma F. Neff

Blood (2021) 138 (Supplement 1): 724.

https://doi.org/10.1182/blood-2021-154531

Published: 2021

Journal Articles

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Solomon A. Graf, Ryan C. Lynch, Chaitra S. Ujjani, Ted A Gooley, David G. Coffey, Andrew J. Cowan, Stephen D. Smith, Mazyar Shadman, Edus H. Warren, Edward Libby, Colin D. Godwin, Alexander L Greninger, Jonathan R. Fromm, Ajay K Gopal

Blood (2021) 138 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2021-153168

Published: 2021

Journal Articles

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

David G. Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, Javier Diaz-Mejia3, Ping Luo, Yong Zhang, Yuexin Xu, Edus H. Warren, Eric L Smith, Hearn Jay Cho, Alexander Lesokhin, Benjamin Diamond, Dickran Kazandjian, Trevor J. Pugh, Damian J. Green, Sacha Gnjatic, Ola Landgren

Blood (2021) 138 (Supplement 1): 329.

https://doi.org/10.1182/blood-2021-154506

Published: 2021

Journal Articles

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Solomon A. Graf, MD, Ryan C. Lynch, MD, Ted A Gooley, PhD, Chaitra S. Ujjani, MD, Peter Wilcox, Sabrina Wilcox, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MDMPH, Edus H. Warren, MD PhD, Edward Libby, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137226

Published: 2020

Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD

Blood (2019) 134 (Supplement_1): 1902.

https://doi.org/10.1182/blood-2019-130990

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

David G. Coffey, MD, Ola Landgren, MD PhD, Yuexin Xu, PhD, Dickran Kazandjian, MD, Trevor J. Pugh, PhD, Sacha Gnjatic, PhD, Edus H. Warren, MD PhD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 4367.

https://doi.org/10.1182/blood-2019-126222

Published: 2019

NARROW

Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab

Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma

Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias

Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase inhibition and CAR T-cell therapy

Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy

Spinal Disease Predicts CNS Involvement in Patients with Plasma Cell Leukemia

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Peripheral Blood Single-Cell Genotyping and Phenotyping in Multiple Myeloma Reveals Shared Mutations across Multiple Hematopoietic Cell Lineages

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only